REYATAZ er i kontrollerede kliniske undersøgelser evalueret for sikkerhed i kombinationsbehandling med andre antiretrovirale lægemidler hos 1. 806 voksne patienter behandlet med REYATAZ 400 mg, én gang dagligt (1. 151 patienter, 52 ugers middelvarighed og 152 ugers maksimal varighed) eller REYATAZ 300 mg med ritonavir 100 mg én gang dagligt (655 patienter, 48 ugers middelvarighed og 101 ugers maksimal varighed).
REYATAZ has been evaluated for safety in combination therapy with other antiretroviral medicinal products in controlled clinical trials in 1,806 adult patients receiving REYATAZ 400 mg once daily (1,151 patients, 52 weeks median duration and 152 weeks maximum duration) or REYATAZ 300 mg with ritonavir 100 mg once daily (655 patients, 48 weeks median duration and 101 weeks maximum duration).